66. IgA nephropathy Clinical trials / Disease details
Clinical trials : 275 / Drugs : 258 - (DrugBank : 82) / Drug target genes : 36 - Drug target pathways : 140
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02282930 (ClinicalTrials.gov) | March 2015 | 31/10/2014 | Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression | An Open-Label Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression | Progressive IgA Nephropathy;Proteinuria | Drug: ACTH (Acthar) Gel | Mayo Clinic | Mallinckrodt | Completed | 18 Years | N/A | All | 20 | Phase 3 | United States |